Minitablets Coated in a Solid-Wall Pan for Theophylline Sustained-Release Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Minitablets Coated in a Solid-Wall Pan for Theophylline Sustained-Release Capsules
The authors describe an alternative approach to compressing and coating minitablets for use in a sustained-release, solid oral-dosage form. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s38-s42

Methods

Preparation of the minitablets. TH, Avicel PH 102, spray-dried lactose, and magnesium stearate in four different ratios (total 4 kg per batch) were blended using an IMA Cyclops blender (IMA, Ozzano, Italy).


Figure 1: Special tooling for minitablets (IMA, Ozzano, Italy). (FIGURE COURTESY OF THE AUTHOR)
Direct compression was performed using a tablet press machine for research and development and small batches (IMA Pressima equipped with 2 EU-D punches fitting 24 minipunches, 2 mm diameter each, (see Figure 1). Compression force used to obtain 9 mg minitablets was maintained at 20 kN for all batches with fill-shoe speed adjusted to 25 rpm.


Table I: Comparison of the two coating formulas.
Coating of minitablets . The coating process of 10 kg of minitablets for each batch was carried out in an IMA GS 25-L solid wall pan (see Figure 2). Two different coating formulas were used (see Table I): a traditional one containing single components to be previously dispersed in water (A) and the ready-to-use pigment dispersion WAS (B).


Figure 2: Schematic of the solid-wall coating pan. (FIGURE COURTESY OF THE AUTHOR)
Coating dispersion A was prepared by homogenizing, in a separate vessel, pigments, plasticizer, and part of the solvent for 10 min. The dispersion obtained was then added to a main vessel containing Eudragit RL/RS and the remaining water and stirred continuously. Coating dispersion B was prepared by simply adding WAS to the main vessel containing Eudragit RL/RS and solvent without the need of predispersion. The coating suspension was than stirred continuously. Both formulas were tested at different polymer amounts expressed in total solids' weight-gain percentage.

The coating process was started by loading the minitablets in the pan manually and without any drum rotation. A preheating phase was carried out at the minimum drum speed to ensure the proper temperature of the cores prior to the spray phase. When the minitablets reached the proper temperature, all the coating dispersion was sprayed by a dedicated compressed-air-fed gun. At the same time, the pan speed was adjusted to the ideal value to avoid the cores sticking or being damaged; mixing was ensured by six shark-fin-type mixing baffles placed in the center of the drum.


Table II: Optimized process parameters for formula A.
During the process, drying was ensured by a special paddle system blowing the correct amount of inlet air at the desired temperature and humidity. Cores were dried from the surface and from the bottom, improving the uniformity of evaporation.


Table III: Optimized process parameters for formula B.
When all the coating dispersion was sprayed, a drying step was performed to reduce the humidity of the cores, then the minitablets were unloaded manually after a short cooling phase. Optimized process parameters for formula A and B are described in Table II and III, respectively.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here